Diretriz preliminar NICE recomenda o uso do inibidor de SGLT2 dapagliflozina para alguns pacientes com doença renal crônica.

NICE recommend dapagliflozin for people with chronic kidney disease – National Institute for Health and Care Excellence

Ver diretriz preliminar:

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version)

Conteúdos relacionados:

NICE Guideline: Assessment and management of chronic kidney disease.

Secondary analysis of RCT finds Dapagliflozin is safe for patients with stage 4 chronic kidney disease.

Randomized trial: Dapagliflozin in patients with chronic kidney disease